Join Growin Stock Community!

Compass therapeutics, inc.CMPX.US Overview

US StockHealthcare
(No presentation for CMPX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CMPX AI Insights

CMPX Overall Performance

CMPX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CMPX Recent Performance

-0.35%

Compass therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

CMPX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CMPX Key Information

CMPX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CMPX Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Price of CMPX

CMPX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CMPX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.48
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
439.25
PB Ratio
4.79
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-6496.82%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.48
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
439.25
PB Ratio
4.79
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-6496.82%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CMPX's latest earnings report released?

    The most recent financial report for Compass therapeutics, inc. (CMPX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CMPX's short-term business performance and financial health. For the latest updates on CMPX's earnings releases, visit this page regularly.

  • How much debt does CMPX have?

    As of the end of the reporting period, Compass therapeutics, inc. (CMPX) had total debt of 9.87M, with a debt ratio of 0.04. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CMPX have?

    At the end of the period, Compass therapeutics, inc. (CMPX) held Total Cash and Cash Equivalents of 46.78M, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • What is the FCF of CMPX?

    Compass therapeutics, inc. (CMPX)'s Free Cash Flow (FCF) for the period is -10.86M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 2.15% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CMPX?

    The latest valuation data shows Compass therapeutics, inc. (CMPX) has a Price-To-Earnings (PE) ratio of -10.33 and a Price/Earnings-To-Growth (PEG) ratio of 0.3. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.